The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I/II study of resiquimod as an immunologic adjuvant for NY-ESO-1 protein vaccination in patients with melanoma.
Rachel Lubong Sabado
No relevant relationships to disclose
Anna C. Pavlick
No relevant relationships to disclose
Sacha Gnjatic
No relevant relationships to disclose
Crystal M Cruz
No relevant relationships to disclose
Isabelita Vengco
No relevant relationships to disclose
Farah Hasan
No relevant relationships to disclose
Farbod Darvishian
No relevant relationships to disclose
Luis Chiriboga
No relevant relationships to disclose
Rose Marie Holman
No relevant relationships to disclose
Juliet Escalon
No relevant relationships to disclose
Caroline Muren
No relevant relationships to disclose
Crystal Escano
No relevant relationships to disclose
Ethel Yepes
No relevant relationships to disclose
Dunbar Sharpe
No relevant relationships to disclose
Sylvia Adams
No relevant relationships to disclose
Patrick Alexander Ott
No relevant relationships to disclose
Achim A Jungbluth
Employment or Leadership Position - Ludwig Institute for Cancer Research
Linda S. Pan
Employment or Leadership Position - Ludwig Insitute for Cancer Research
Ralph Rudolph Venhaus
Employment or Leadership Position - Ludwig Institute for Cancer Research
Nina Bhardwaj
No relevant relationships to disclose